Filing Details
- Accession Number:
- 0001179110-13-007705
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-05-03 17:33:56
- Reporting Period:
- 2013-05-01
- Filing Date:
- 2013-05-03
- Accepted Time:
- 2013-05-03 17:33:56
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1436304 | Kythera Biopharmaceuticals Inc | KYTH | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1559510 | Keith Klein | C/O Kythera Biopharmaceuticals, Inc. 27200 West Agoura Road, Suite 200 Calabasas CA 91301 | General Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2013-05-01 | 9,000 | $0.76 | 9,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2013-05-01 | 9,000 | $23.63 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2013-05-01 | 9,000 | $0.00 | 9,000 | $0.76 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
9,152 | 2016-12-05 | No | 4 | M | Direct |
Footnotes
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan which expires April 30, 2014.
- The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.22 to $24.20, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- 100% of the shares subject to the option are fully vested and exercisable.